Compare Merck & Co., Inc. (MRK) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Wynn Resorts, Limited — how do they compare? Merck & Co., Inc. trades at $133.42 (market cap $321.77B), while Wynn Resorts, Limited trades at $103.25 (market cap $10.79B). The key difference: Merck & Co., Inc. is far larger — about 29.8× Wynn Resorts, Limited's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | WYNN | |
|---|---|---|
Market Cap | $321.77B | $10.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $131.84 | $133.34 |
52-Week Low | $77.60 | $94.37 |
Enterprise Value | $368.53B | $21.03B |
Dividend Yield | 2.61% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Wynn Resorts (WYNN) trades at $103.51, up 0.99% today, showing steady recovery from pandemic lows. The stock maintains bullish technical signals with strong institutional support, though faces headwinds from high debt levels and margin pressure. Recent Q2 2026 earnings beat expectations with $1.24 EPS versus $0.99 estimate, driven by Macau strength, while Las Vegas operations show slower growth. Analyst consensus remains strongly bullish with 64% buy ratings and $133 price target, representing 28% upside potential.
Investment outlook balances growth potential against significant risks. The company's Macau recovery and UAE expansion provide growth catalysts, but high leverage ($10.5B debt) and rising capex for Wynn Al Marjan project create cash flow pressure. Current valuation at 25x P/E appears reasonable given recovery trajectory, but investors should monitor margin trends and capital expenditure discipline closely given the negative shareholder equity position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
